Curtana Pharmaceuticals, Inc.
USPTO PatentsView assignee record - 5 granted patents across 3 technology areas, recorded in grant years 2019–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).
The verdict
According to USPTO PatentsView, Curtana ranks #45,976 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 3 technology areas.
- #45,976
- of 49,997 US assignees by volume
- Top 39%
- by Innovation Score (39.3/100)
- 11.6
- avg claims per patent
- +300%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R45976 · US Corporation #45,976 · 5 grants
GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-PAR · TYPE-USCORP · VEL-SURGE · BOOK-FULL
- GRANTS-MICRO 5 grants
- BOTTOM-DECILE #45,976/49,997
- PHOTO-FINISH Curadigm SAS
- CPC-NARROW C07D · 3 areas
- INNOV-THIN 39.3/100
- CLAIMS-PAR 11.6 claims/avg
- TYPE-USCORP US Corporation
- VEL-SURGE +300% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Curadigm SAS (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Curtana’s 39.3 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Curtana
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Curtana Pharmaceutic… · this assignee
Curtana Pharmaceutic… · this assignee
39 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Curtana's Innovation Score is 39.3/100 (top 39% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Curtana?
Each dot is one of Curtana’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Curtana’s own 11.6 claims/patent is ABOVE the 10.4 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Curtana's grants concentrate
Curtana Pharmaceuticals, Inc. is a focused PatentsView assignee: 3 CPC subclasses with 100% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2023 (2 grants) versus a trough of 1 in 2019. By volume, Curtana sits between Curadigm SAS and CVI Laser, LLC.
Curtana's three-year grant acceleration
Curtana Pharmaceuticals, Inc. shows 4 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Curtana's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Curadigm SAS
Curadigm SAS
5 patents
- Curamys
Curamys Inc.
5 patents
- Curetis
Curetis GMBH
5 patents
- Current Health
Current Health Limited
5 patents
- Cuz-d Manufacturi…
Cuz-d Manufacturing, Inc.
5 patents
- Cuztom Kraft PTY
Cuztom Kraft PTY Ltd
5 patents
- CV Sciences
CV Sciences, Inc.
5 patents
- CVI Laser
CVI Laser, LLC
5 patents
- Curtana Pharmaceu… ◀
Curtana Pharmaceuticals, Inc.
5 patents
What this shows Curtana holds 5 patents at rank #45,693, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Curtana
By rank, the assignees closest to #45,693 in granted patent volume.
- Curadigm SAS #45,689 · 5 patents
- Curamys Inc. #45,690 · 5 patents
- Curetis GMBH #45,691 · 5 patents
- Current Health Limited #45,692 · 5 patents
- Cuz-d Manufacturing, Inc. #45,694 · 5 patents
- Cuztom Kraft PTY Ltd #45,695 · 5 patents
- CV Sciences, Inc. #45,696 · 5 patents
- CVI Laser, LLC #45,697 · 5 patents
Leaders in C07D (Heterocyclic Compounds)
Other assignees with the most granted patents in Curtana's primary technology class.
Curtana's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
39 Top 39% higher than 61% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2019 | 1 | 20.0% |
| 2022 | 1 | 20.0% |
| 2023 | 2 | 40.0% |
| 2024 | 1 | 20.0% |
Which technologies does Curtana Pharmaceuticals, Inc. patent most?
Top 3 of 3 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Curtana Pharmaceuticals, Inc.'s patent record in context - here's where to go next.
- Curtana Pharmaceuticals, Inc.'s lead technology class is C07D (Heterocyclic Compounds), 100% of its portfolio - see every assignee active in that class. Explore C07D
- Ranked #45,976 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Curtana Pharmaceuticals, Inc. against Curadigm SAS, an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 39.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.